Arena Pharmaceuticals Inc (ARNA.O)

ARNA.O on Nasdaq

17 Apr 2014
Price Change (% chg)

$-0.12 (-1.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ARNA.O


Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s... (more)


Beta: -0.33
Market Cap (Mil.): $1,355.03
Shares Outstanding (Mil.): 219.26
Dividend: --
Yield (%): --


  ARNA.O Industry Sector
P/E (TTM): -- 25.73 33.35
EPS (TTM): -0.09 -- --
ROI: -7.77 -2.92 18.92
ROE: -20.40 -12.17 19.68
Search Stocks

MARKET PULSE-3D Systems, Medivation, Plug Power, Arena Pharma

U.S. stocks rose on Friday as some positive economic data boosted the S&P 500 to record levels for a second straight day and put major indexes on track for strong gains in both the week and the month. The Dow Jones industrial average was up 0.49 percent at 16,351.94, the S&P 500 was up 0.48 percent at 1,863.17 and the Nasdaq Composite was up 0.27 percent at 4,330.511.

28 Feb 2014

CORRECTED-BRIEF-Arena Pharmaceuticals qtrly loss per share $0.11 (Feb 27)

(Corrects second bullet in Feb 27 item to say the company expects revenue of $9 mln from amortization of collaboration payments in 2014, not total revenue. Arena did not forecast total revenue) Feb 27 - Arena Pharmaceuticals Inc : * Provides corporate update and reports fourth quarter and full year 2013 financial results * Sees FY 2014 revenue of about $9 million from amortization of upfront payments from existing collaborations * Qtrly total revenues $6.5 million versus $1.9 millio

28 Feb 2014

Eisai to sell Arena's diet pill in most markets worldwide

- Arena Pharmaceuticals Inc said Japanese drugmaker Eisai Co Ltd will market its diet drug in most markets worldwide as part of an expanded agreement, under which the companies will also develop the drug for other indications.

07 Nov 2013


  Price Change
Roche Holding Ltd. (ROG.VX) CHF254.90 +0.70
GlaxoSmithKline plc (GSK.L) 1,559.00p -4.50
Orexigen Therapeutics, Inc. (OREX.OQ) $5.30 -0.08
VIVUS, Inc. (VVUS.OQ) $5.36 +0.11

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Pechala's Reports
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks